Twist Bioscience reported first‑quarter revenue of $103.7 million, up 17% year‑over‑year and $0.9 million above the consensus estimate of $102.8 million. The top‑line growth was driven by a 27% year‑over‑year increase in DNA synthesis and protein solutions revenue, which reached $51.1 million, reflecting strong demand from AI‑enabled discovery and other high‑margin segments.
The company posted a loss of $0.50 per share, missing the consensus estimate of $-0.49 by $0.01. The EPS miss was largely due to higher operating expenses from strategic investments in sales, digital infrastructure, and research and development, which offset the benefit of an improved gross margin of 52.0% versus 51.3% in the prior quarter.
Gross margin expanded to 52.0% from 51.3% in Q4 FY2025, driven by a higher mix of high‑margin AI and protein solutions and operational leverage as the silicon‑based synthesis platform scales. The margin improvement helped offset the impact of increased costs on profitability.
Management raised full‑year 2026 revenue guidance to $435–$440 million, up from the previous $425–$430 million range, signaling confidence in sustained demand. The company reiterated its path to adjusted EBITDA break‑even in Q4 FY26, underscoring a focus on cost discipline and margin expansion.
Investors responded favorably to the results, with analysts noting the revenue beat and the upward revision of guidance as key positives, while acknowledging the EPS miss as a short‑term challenge.
CEO Emily Leproust highlighted AI‑driven discovery as a primary growth engine, and CFO Adam Laponis emphasized improving cash flow from operations and continued focus on cost discipline to support the company’s long‑term profitability goals.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.